Merger & Acquisition in Pharmaceuticals & Healthcare Industry: Encorium Group, Inc. (ENCO)

• Publication date: June 2012
• Report size: 77 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. Encorium Group, Inc. (ENCO) SWOT Analysis report provides you a strategic analysis and detailed overview of the company’s businesses and operations. In this report, our analysts reveal the co...

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days.

Encorium Group, Inc. (ENCO) SWOT Analysis report provides you a strategic analysis and detailed overview of the company’s businesses and operations.

In this report, our analysts reveal the company’s business strategy, strengths, weakness, opportunities and threats and detailed information such as :
- Key events associated with the company,
- Major products, services and brands of the company,
- Key competitors,
- Key executives, biographies and employment history,
- Personnel heading key departments and functions,
- Important locations and subsidiaries
- Financial analysis and ratios based on the annual financial statements published by the company including a 5 years history.
- Interim ratios for the last five interim periods

You get also in deepth information about Encorium Group, Inc. (ENCO) operations to identify potential customers, partners and suppliers. Encorium Group, Inc. (ENCO) business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Pathology Industry

Data table of Contents
Data table of Contents 2
List of Tables 5
List of Figures 5
Encorium Group, Inc., Pharmaceuticals & Healthcare, Deals By Year, from 2005 to 2011 6
Encorium Group, Inc., Pharmaceuticals & Healthcare Deals By Type, from 2005 to 2011 7
Encorium Group, Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal By Region, from 2005 to 2011 8
Encorium Group, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, from 2005 to 2011 9
Encorium Group, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, from 2005 to 2011 10
Encorium Group, Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal Summary, from 2005 to 2011 11
Encorium Group, Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal Details 12
Partnerships 12
Encorium Forms Joint Venture With Prosoft Software 12
Oramed Pharmaceuticals Enters Into Co-Development Agreement With Encorium Group 13
Encorium Group Enters Into Co-March keting Agreement With AtCor Medical Holdings 14
Encorium Group Enters Into Co-Development Agreement With Emergent BioSolutions 15
Equity Offering 16
Encorium Group Extends Rights Offering For US$ 10 Mln 16
Encorium Group Completes Private Placement Of US$ 1.58 Mln 18
Encorium Group Completes Private Placement Of US$ 5 Mln 19
Divestiture - Assets 21
Encorium Completes Sale Of Its US Business To Pierrel 21
Acquisition 22
Encorium Group Takes Over Progenitor International Research 22
Encorium Group Takes Over Remedium 23
Key Competitors 24
Key Employees 24
Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 27
Strategy And Business Planning 27
May 10, 2010: Encorium Wins US$ 6.8 Mln In New Business Contract Including Two Pivotal Phase III Studies 27
Financial Announcements 27
August 17, 2010: Encorium Reports Net Loss Of US$ 0.8 Mln For Q2 2010 27
May 18, 2010: Encorium Reports Total Sales s Of US$ 3.5 Mln In Q1 2010 27
May 14, 2007: Encorium Reports 2007 First Quarter Financial Results Raises 2007 Net Sales Guidance To US$ 32-$34 Mln 28
March 19, 2007: Encorium Group Reports 2006 Fourth Quarter And Year End Financial Results 29
August 08, 2006: Covalent Reports 2006 Second Quarter Financial Results 29
May 16, 2006: Covalent Reports 2006 First Quarter Financial Results And Summary Balance Sheet Data 31
August 11, 2005: Covalent Reports Results For Second Quarter 2005 32
May 16, 2005: Covalent Reports Results For First Quarter 2005 33
March 29, 2005: Covalent Reports Results For 2004 34
March 16, 2005: Covalent Reports Results For First Quarter 2005 35
November 15, 2004: Covalent Reports Results For Third Quarter 2004 36
August 30, 2004: Covalent Group Announces Cost Reduction Initiatives. Firms Reiterates 2004 Goal Of US$ 30 Mln In New Business 37
August 10, 2004: Covalent Group Reports Results For Second Quarter 2004 37
May 11, 2004: Covalent Reports Results For First Quarter 2004 38
March 31, 2004: Covalent Group Inc Announces Annual Report 39
March 10, 2004: Covalent Reports Results For 2003 40
November 13, 2003: Covalent Group Quarterly Report For Period Ended September tember 30, 2003 41
November 12, 2003: Covalent Reports Results For The Third Quarter 2003 43
August 13, 2003: Covalent Group Quarterly Report For Period Ended June e 30, 2003 44
August 11, 2003: Covalent Reports Results For The Second Quarter 2003 45
May 14, 2003: Covalent Group Quarterly Report For Period Ended March ch 31, 2003 46
May 12, 2003: Covalent Reports Results For First Quarter 2003 47
March 31, 2003: Covalent Group Inc Annual Report For The Year 2002 48
March 11, 2003: Covalent Reports Record Results For 2002 50
November 13, 2002: Covalent Group Publishes Quarterly Report For Period Ended September tember 30, 2002 51
November 12, 2002: Covalent Reports Increases In Third Quarter 2002 52
August 13, 2002: Managements Discussion And Analysis Of Financial Condition And Results Of Operations 53
August 13, 2002: Covalent Announces Record Second Quarter Results 55
May 15, 2002: Managements Discussion And Analysis Of Financial Condition And Results Of Operations 55
May 14, 2002: Covalent Group, Inc. Announces Strong Financial Results For The First Quarter 2002; 45% Increase In Net Sales And 57% Increase In Earnings 57
April 01, 2002: Managements Discussion And Analysis Of Results Of Operations And Financial Condition 57
March 13, 2002: Covalent Group, Inc. Announces Record Operating Results For Fourth Quarter And Year 2001 59
Corporate Communications 60
October 22, 2010: Encorium Announces NASDAQ Panel December ision To Delist Common Stock; Announces Changes To Board 60
April 28, 2010: Encorium Receives Delisting Notice From NASDAQ 60
January 14, 2010: Encorium Re-Appoints Kai Lindevall As CEO 61
September 10, 2008: Encorium Appoints David Ginsberg As President And CEO 61
Product News 61
December 15, 2003: Covalent Group Announces Cardiovascular Safety Study And Other Contracts Totaling US$ 8.1 Mln 62
December 08, 2005: Covalent Group, Inc. Signs Letter-Of-Intent To Conduct US$ 2.2 Mln Multinational Phase 2 Clinical Trial In Cardiovascular Disease 62
November 15, 2004: Covalent Group, Inc. Makes Important Contributions To Clinical Research Trial Suggesting That ‘normal’ Blood Pressure In Patients With Coronary Heart Disease May Still Be Too High 62
November 13, 2003: Covalent Group, Inc. Successfully Concludes Landmark Clinical Research Trial In Coronary Atherosclerosis 63
October 19, 2009: Encorium Group, Inc. Completes US$ 1.6 Mln Private Placement Of Common Stock And Executes Warrant Exchange Agreement; Ends Discussions To Sell Encorium Oy 64
October 06, 2005: Covalent Group, Inc. Announces US$ 5.3 Mln Contract To Provide Additional Services For A World Phase 3 Trial In Hypertension 64
August 13, 2008: Encorium Group Signs US$ 3.5 Mln Of New Contracts For Vaccines Clinical Trials US$ 13.5 Mln Of New Business Contracts Announced During The Past Three Weeks 65
August 11, 2003: Covalent Group, Inc. Announces US$ 2.2 Mln Clinical Research Contract 65
July 17, 2009: Encorium Group Completes Sale Of Its U.S. Business To Pierrel Research Usa; Announces Management Changes 65
July 12, 2007: Encorium Group, Inc Announces US$ 1.7 Mln Contract With Japanese Biotechnology Firms For Phase 2 Clinical Trial For Major Depressive Disorder 66
July 01, 2002: Covalent Group, Inc. Announces US$ 1.2 Mln Clinical Research Contract To Conduct Phase Iv Study For Treatment Of Gastrointestinal Diseases 66
June 22, 2005: Covalent Group, Inc. Awarded Major Multi-National Clinical Research Program In Cardiovascular Disease Announces US$ 9.2 Mln In Contracts As Part Of A Multi-Study Program 66
June 21, 2007: Encorium Group, Inc. Announces US$ 3.8 Mln Contract For Phase 2 Clinical Trial In Herpes Zoster (Shingles) 67
June 18, 2009: Encorium Group Provides Update To Loi With Respect To The Sale Of Its U.S. Business 67
June 12, 2008: Encorium Group, Inc. Announces Signing Of Letter Of Intent To Combine With Linkcon; Expected Expansion Will Create World Cro 68
May 30, 2002: Covalent Group, Inc. Adds US$ 1.3 Mln In New Services To A US$ 6.3 Mln Clinical Trials Contract 68
May 14, 2002: Covalent Group, Inc. Announces Contracts For US$ 1.35 Mln To Provide Services For Two Clinical Studies To Be Conducted Exclusively In Europe 69
May 12, 2004: Covalent Group, Inc. Awarded Major Clinical Research Program With Leading Biopharmaceutical Firms Announces US$ 2.0 Mln Initial Phase Of A Multi-Study Program 69
May 03, 2004: Covalent Group Signs US$ 1.0 Mln Contract To Study Vaccine Against Plague - Firms ’s Third Counter-Bioterrorism Contract 70
May 03, 2004: Covalent Group Signs US$ 1.1 Mln Contract To Study Counter-Bioterrorism Vaccine Against Venezuelan Equine Encephalitis 70
April 28, 2008: Encorium Group, Inc. Expands Its European Operations With The Opening Of An Office In The Cologne Area, Germany, Encorium Germany Gmbh 70
April 20, 2006: Covalent Group, Inc. Signs US$ 1 Mln Contract To Conduct Phase 1 Study Of Drug To Prevent/Treat Infectious Disease 70
April 03, 2002: Covalent Group, Inc. Announces Contracts For US$ 4.8 Mln To Provide Nda Submission And Additional Clinical Trial Services 71
April 03, 2002: Covalent Group Gets US$ 4.8 Mln Pacts For Nda, Trial Services 71
March 06, 2002: Covalent Group Gets US$ 2.7 Mln Pact For Clinical Trial 71
February 26, 2004: Covalent Group Announces US$ 4.8 Mln In New Clinical Research Contracts 71
February 03, 2003: Covalent Group, Inc. Announces US$ 3.2 Mln Of New Clinical Trial Contracts 72
February 02, 2006: Covalent Group, Inc. Signs US$ 2.2 Mln Contract With New Sponsor To Conduct Clinical Trial In Patients With Cardiovascular Disease 72
January 27, 2009: Encorium Group Signs US$ 3.1 Mln Of New Business Contracts Including An Extension Of A Current U.S. Oncology Clinical Trial With A Major Pharmaceutical Firms 73
January 18, 2006: Covalent Group, Inc. Signs Contract For US$ 2.3 Mln To Conduct A Multinational Phase 2 Clinical Trial Involving A New Antithrombotic Agent 73
January 10, 2008: Encorium Group, Inc. Announces Signing Of US$ 1.7 Mln In Contracts With Leading International Biotechnology Firms For Clinical Trials In Oncology And Rheumatology 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75


List of Tables

Encorium Group, Inc., Pharmaceuticals & Healthcare, Major development, 2009 1
Encorium Group, Inc., Pharmaceuticals & Healthcare, Deals By Year, from 2005 to 2011 1
Encorium Group, Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal By Region, from 2005 to 2011 1
Encorium Group, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, from 2005 to 2011 1
Encorium Group, Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal Summary, from 2005 to 2011 1
Encorium Group, Inc., Pharmaceuticals & Healthcare, Deals By Year, from 2005 to 2011 6
Encorium Group, Inc., Pharmaceuticals & Healthcare Deals By Type, from 2005 to 2011 7
Encorium Group, Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal By Region, from 2005 to 2011 8
Encorium Group, Inc., Deals By Therapy Area, from 2005 to 2011 9
Encorium Group, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, from 2005 to 2011 10
Encorium Group, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, from 2005 to 2011 10
Encorium Group, Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal Summary, from 2005 to 2011 11
Encorium Forms Joint Venture With Prosoft Software 12
Oramed Pharmaceuticals Enters Into Co-Development Agreement With Encorium Group 13
Encorium Group Enters Into Co-March keting Agreement With AtCor Medical Holdings 14
Encorium Group Enters Into Co-Development Agreement With Emergent BioSolutions 15
Encorium Group Extends Rights Offering For US$ 10 Mln 16
Encorium Group Completes Private Placement Of US$ 1.58 Mln 18
Encorium Group Completes Private Placement Of US$ 5 Mln 19
Encorium Completes Sale Of Its US Business To Pierrel 21
Encorium Group Takes Over Progenitor International Research 22
Encorium Group Takes Over Remedium 23
Encorium Group, Inc., Key Executives 24
Encorium Group, Inc., Other Locations 25


List of Figures

Encorium Group, Inc., Pharmaceuticals & Healthcare, Deals by Type, from 2005 to 2011 1
Encorium Group, Inc., Pharmaceuticals & Healthcare, Deals By Year, from 2005 to 2011 6
Encorium Group, Inc., Pharmaceuticals & Healthcare, Deals by Type, from 2005 to 2011 7
Encorium Group, Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal By Region, from 2005 to 2011 8
Encorium Group, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, from 2005 to 2011 9

Companies mentioned
Stratus Pharmaceuticals, Inc.
Cupron, Inc.
LaRon Pharma Inc.
Rapides Healthcare System, L.L.C.
Outcomes Research Consortium
Chiral Quest, Inc.
Quantitative Technologies, Inc.
Theradex Systems, Inc.
Astrogenetix, Inc.
Memorial University Medical Center
Transfusion Management Services, Inc.
Consumer Product Testing Co., Inc.
Symbion Research International, Inc.
Camargo Pharmaceutical Services, LLC